AstraZeneca’s Imfinzi in combination with carboplatin and paclitaxel followed by Imfinzi monotherapy has been approved in the U.S. as treatment for adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair deficient, or dMMR, the company announced. Dave Fredrickson, Executive Vice President, Oncology Business Unit, AstraZeneca, said: “There have been limited advances in the treatment of endometrial cancer in the last few decades, and continued innovation is critical as the burden of this cancer is expected to grow in the future. Immunotherapy in combination with chemotherapy is emerging as a new standard of care in this setting, and the approval of Imfinzi offers an important new option for patients with mismatch repair deficient disease.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AZN:
- AstraZeneca’s Farxiga approved by FDA to treat pediatric diabetes
- AstraZeneca price target raised to 15,000 GBp from 13,000 GBp at Berenberg
- FDA grants priority review to AstraZeneca’s Tagrisso for EGFRm NSLC
- AstraZeneca’s sNDA for Tagrisso granted Priority Review in U.S.
- AstraZeneca Completes Fusion Pharmaceuticals Acquisition